





























Link to publication record in King's Research Portal
Citation for published version (APA):
Brown, A. A., Viñuela, A., Delaneau, O., Spector, T. D., Small, K. S., & Dermitzakis, E. T. (2017). Predicting
causal variants affecting expression by using whole-genome sequencing and RNA-seq from multiple human
tissues. Nature Genetics, 49(12), 1747-1751. https://doi.org/10.1038/ng.3979
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Predicting causal variants affecting 1 
expression using whole genome 2 
sequence and RNA-seq from multiple 3 
human tissues 4 
 5 
Andrew Anand Brown1,2,3,4,*, Ana Viñuela1,2,3, Olivier Delaneau1,2,3, Tim D 6 
Spector1,2,3, Kerrin S Small5, Emmanouil T Dermitzakis1,2,3,* 7 
 8 
1Department of Genetic Medicine and Development, University of 9 
Geneva Medical School, Geneva, Switzerland. 10 
2Institute for Genetics and Genomics in Geneva (iGE3), University of 11 
Geneva, Geneva, Switzerland. 12 
3Swiss Institute of Bioinformatics, Geneva, Switzerland. 13 
4NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University 14 
Hospital, Oslo, Norway. 15 
5Department of Twin Research and Genetic Epidemiology, King's 16 
College London, St Thomas' Campus, London, United Kingdom. 17 




Genetic association mapping produces statistical links between phenotypes and genomic 22 
regions, but identifying causal variants remains difficult. Complete knowledge of all genetic 23 
variants, as provided by whole genome sequence (WGS), will help, but is financially prohibitive 24 
for well powered GWAS studies. We performed eQTL mapping using WGS and RNA-seq, and 25 
showed lead eQTL variants called using WGS are more likely to be causal. We derived 26 
properties of causal variants using simulations, and used these to propose a method for 27 
implicating likely causal SNPs. We estimate that 25% - 70% of causal variants lie in open 28 
chromatin regions, depending on tissue and experiment. Finally, we identify a set of high 29 
confidence causal variants and show they are more enriched in GWAS associations than other 30 
eQTLs. Of these, we find 65 associations with GWAS traits, giving examples where the gene 31 
implicated by expression has been functionally validated as relevant for complex traits. 32 
Genome-wide associations studies (GWAS) have uncovered 1,000s of genetic associations 33 
between regions of the genome and complex traits1, but moving from the association to 34 
identifying the mechanism behind it has proven complicated2. Statistical associations between 35 
traits and genomic regions indicate a variant with a causal effect on the trait, as reverse 36 
causation or unmeasured confounders modifying DNA can be ruled out (we interpret causal 37 
effect in the probabilistic sense, where a direct intervention modifying one factor has 38 
consequences on another). A first step for understanding the mechanism would be to identify 39 
the exact variant, as exact localisation would allow exploration as to which transcription factor 40 
binding sites and regulatory elements are affected. This, however, is complicated by the fact 41 
that most loci tested in GWAS studies are not directly measured, but instead imperfectly 42 
imputed3. Whole-genome sequence (WGS) data does directly ascertain all genotype calls, but 43 
despite falling costs is still very expensive on the sample sizes of modern GWAS studies 44 
(Supplementary Table 1). In contrast, eQTL studies linking variants and gene expression have 45 
discovered 1,000s of associations using few hundreds of samples, a scale at which collecting 46 
whole genome sequence data is feasible4. 47 
We describe analysis combining for the first time two previously published datasets derived 48 
from individuals in the TwinsUK cohort: RNA-seq from four tissues5,6 and WGS from the UK10K 49 
project7 (previously, gene expression quantified using micro-arrays8 has been combined with 50 
the same whole genome sequence dataset for specific look-ups of GWAS associations9,10). We 51 
explore the properties of causal variants using simulations,  and propose the CaVEMaN 52 
method (Causal Variant Evidence Mapping using Non-parametric resampling) to estimate the 53 
probability that the variant most associated with the expression trait is causal for that 54 
association.  We use this to produce a robust set of likely causal SNPs; this could be an 55 
important resource for developing methods to call personalised regulatory variants from 56 
whole-genome sequence and sequence annotations. 57 
With whole genome sequence, genotypes are directly measured at a far more sites than are 58 
available on current genotyping chip arrays (although sites on a genotyping chip should be 59 
measured with more accuracy). The 1000 Genomes project estimate they observe > 99% of 60 
SNPs with minor allele frequency greater than 1%. For low coverage sequencing and 61 
genotyping arrays, imputation methods are frequently used to impute better quality calls at 62 
sites with no coverage on the arrays and low or no coverage with sequence data. The degree 63 
to which, if at all, information at more sites from sequence reduces imputation noise and 64 
increases power to map eQTLs is currently unknown. For a simple comparison, we mapped 65 
independent eQTLs within 1Mb of the transcription start site for protein coding genes and 66 
lincRNAs in four tissues (fat, lymphoblastoid cell lines (LCLs), skin and whole blood) using 67 
individuals for which expression, sequence and genotype array data were all available (N from 68 
242 (whole blood) to 506 (LCLs)). We identify 27,659 independent autosomal eQTLs affecting 69 
11,865 genes using whole genome sequence (8,690,715 variants), and 26,351 affecting 11,642 70 
genes using genotypes called from arrays and imputed into the 1000 Genomes Project Phase 1 71 
reference panel (6,263,243 variants) (Figure 1, an analysis of all individuals with expression 72 
and WGS data (N from 246-523) and including the X chromosome found 28,141 eQTLs 73 
affecting 12,243 genes). This means just a 3.7% increase in discovered eQTLs using WGS; 74 
balanced against at least a ten-fold increase in cost of collecting the data, it does not seem a 75 
worthwhile exercise yet. This demonstrates the ability of imputation approaches to accurately 76 
assay common variation, particularly since the denser genotyping arrays and larger reference 77 
panels now available would reduce and possibly even remove this difference (more details on 78 
imputation accuracy is available in the Online Methods). 79 
We frequently observe that the lead eQTL variant (LEV, the variant most associated with the 80 
trait) differs between the two datasets. As genotypic uncertainty should be reduced for WGS, 81 
we expect the WGS LEVs to be the causal variant more frequently than LEVs from genotype 82 
arrays. To test this hypothesis, we looked for enrichment of WGS-derived LEVs relative to 83 
array-genotype-derived in biochemically active regions of the genome. Indeed, for 30 out of 84 
31 experiments carried out by the Roadmap Epigenomics consortium11 in relevant tissues, we 85 
see significant enrichment of sequence LEVs compared to genotype LEVs falling in DNase1 86 
hypersensitivity sites (DHS) (Odds ratio, 1.17-1.40, Figure 2). From this we infer that the LEVs 87 
called with our sequence are more likely the causal variant. 88 
To better understand properties of causal variants we simulated expression datasets where 89 
the causal variant is known, with properties matched to those of the LEVs from the original 90 
eQTL mapping with sequence genotypes (considering effect size, distance to the transcription 91 
start site and minor allele frequency). Repeating the eQTL mapping on these simulated 92 
datasets, we found that in 45% of cases the causal variant was the LEV. This number was 93 
consistent across tissues, despite sample size and power to map eQTLs being much reduced 94 
for whole blood (Supplementary Figure 1). This number is also similar to that obtained from 95 
the analysis of the Geuvadis data (55%), using a different methodology. We also see a rapid 96 
decline forlower ranked candidate variants, the 10th most associated SNP is causal in only 1% 97 
of cases. 98 
Our simulations show that across all genes, the LEV is a strong candidate for the causal 99 
variant. However, for specific LEVs, causality will depend on the linkage disequilibrium 100 
structure around the true causal variant and phenotypic uncertainty in expression of the 101 
particular gene. For these reasons we developed the CaVEMaN method, which uses bootstrap 102 
methods similar to those previously proposed by others12,13 to estimate the probability that 103 
the LEV is the causal variant (see Online Methods for methodological details). 104 
We applied the CaVEMaN method to all four tissues and the Geuvadis LCL RNA-seq data (N = 105 
445, results in Supplementary Data Set 1). The distributions of probabilities that LEVs are 106 
causal are similar across tissues and studies (Figure 3). For 7.5% of the eQTLs the LEV has P > 107 
0.8 of being the causal variant, we refer to these as High Confidence Causal Variants (HCCVs). 108 
For comparison, we applied the CAVIAR method14 to the largest dataset (TwinsUK LCLs), and 109 
dap-g15 to simulated data (full details in the Online Methods). 110 
To understand more about the relationship between causal regulatory variation and active 111 
genomic regions found by ChIP-seq in single individuals, we integrated our causal probabilities 112 
with DHSs from the Roadmap Epigenomics consortium. Figure 4 shows a simple linear 113 
relationship between the causal probability of the LEV and the probability that the LEV is 114 
located in a DHS (though low probability blood eQTLs (P < 0.25) are found less often in DHSs 115 
than expected by the linear model, possibly due to these LEVs being less reliable due to the 116 
smaller sample size). We exploit the linear relationship to estimate the proportion of 117 
regulatory variants with causal probability 1 that lie within DHS identified by particular 118 
experiments. Figure 5 shows that for all tissues except blood, only a minority of regulatory 119 
variants lie within DHS called by specific experiments. Blood eQTLs, discovered in a smaller 120 
sample size than the other tissues, have larger effect sizes and thus are more likely to affect 121 
promoter activity, a possible explanation for the observed greater enrichment. When 122 
CaVEMaN is applied to larger eQTL datasets, with power to discover eQTLs with more subtle 123 
effects, it is possible the proportion of causal regulatory variants in DHSs will be even lower, 124 
implying limited utility of regulatory annotations for interpretation of enhancer and weaker 125 
regulatory variants. 126 
It is widely known that associations with whole organism traits, as discovered by GWAS, are 127 
enriched in eQTLs20; by defining a set of eQTLs where the causal variant is known with high 128 
probability, these could show greater enrichment (a shared GWAS-eQTL signal would not be 129 
diluted by linkage). In addition, by providing both a mediating gene and a variant causative for 130 
the expression signal, these results could provide a more mechanistic understanding of GWAS 131 
signal.  We extracted P values for association for all of the LEVs from 16 GWAS studies with 132 
publicly available summary statistics (see Online Methods) and saw greater enrichment of 133 
small P values for HCCVs compared to all other eQTLs (π1 = 16.2 compared with π1 = 14.0, 134 
estimated using qvalue21). Greater enrichment was also observed when considering the 135 
proportion of shared signals between GWAS associations with P < 5×10-8 listed in the NHGRI 136 
catalogue and eQTLs falling in the same recombination hotspot (16.0% of proximal HCCVs and 137 
GWAS associations were shared, 2.49% for all other eQTLs, estimated using the Regulatory 138 
Concordance method22,23 (RTC)). We also found Bonferroni significant GWAS associations 139 
between 53 HCCVs and 65 GWAS traits (P < 3×10-6, Figure 6, Supplementary Data Set 2). 140 
Applying the coloc method to test whether the eQTL and GWAS trait are affected by the same 141 
causal variant24, we observe 18 cases where there is strong evidence of common genetic 142 
effects (coloc probability > 0.95) and 29 cases with at least moderate evidence (coloc 143 
probability > 0.7). 144 
Given these examples of variants with highly confident causal effects on expression and 145 
statistical associations with GWAS traits, functional evidence connecting the expression of the 146 
gene with the trait would also implicate a causal link between variant and trait. For example, a 147 
HCCV (rs10274367, all rs IDs are as defined in dbSNP, build 148, GRCh37) associated with 148 
GPER1 is also associated with levels of high-density lipoprotein (HDL) cholesterol (coloc 149 
estimate of shared causal variant = 0.999). Female knock-out mice for the gene show a 150 
decrease in HDL levels25. We also found rs1805081 to be a HCCV for NPC1, and the lead 151 
associated variant with BMI in a large GWAS study26 (coloc probability = 0.722). Heterozygous 152 
mouse models (Npc1+/-), where the gene is expressed at half normal levels, observe large 153 
weight gain on high fat diets but not on low fat diets27,28, and higher levels of NPC1 in human 154 
adipose tissue normalise after bariatric surgery and behavioural modification29. In this 155 
example, the expression of NPC1 is modified by rs1805081 and hypothesised to be a response 156 
to changes in BMI. Expression changes in NPC1 seem to be part of a compensatory mechanism 157 
to modify the weight gain due to dietary excesses and the result of diet-by-genotype 158 
interactions. Finally, we observe rs4702 as a HCCV for the FURIN gene in our analysis and it 159 
was the lead variant in the GWAS study of schizophrenia30, coloc probability = 0.999). Altering 160 
expression of FURIN was seen to produce neuro-anatomical deficits in zebrafish and abnormal 161 
neural migration in human induced pluripotent stem cells31. 162 
This paper has produced a method for looking for causal variants for expression. However a 163 
HCCV associated with a GWAS trait does not necessarily mean that they shares a common 164 
causal variant, or the causal mechanism acts in the tissue under study. However, combining 165 
fine-mapping using CaVEMaN with co-localisation methods that formally test whether genetic 166 
variants between traits are shared22,24 and methods which aim to predict causal tissues23,32 167 
could pinpoint precise variants, genes and tissues underlying GWAS traits. Also, methods for 168 
fine-mapping and for testing for co-localisation share common features. Similarly to how fine-169 
mapping method (CAVIAR14) was extended to test for co-localisation (eCaviar32), CaVEMaN 170 
could also be extended to test for co-localisation. 171 
In summary, we have produced a method to estimate the probability that the lead eQTL 172 
variant is the causal variant. We have used this method to estimate the effectiveness of ChIP-173 
seq experiments from a single individual in predicting regions which harbour regulatory 174 
variation, and also to suggest variants which may be causal for GWAS associations. This 175 
method could also be applied to GWAS studies, learning candidate causal variants for whole 176 
organism traits. Pinpointing the causal variant in such studies will facilitate the integration of 177 
these association signals with mechanistic regulatory interactions and likely upstream 178 
regulators, and also allow the development of interpretation methods from genome sequence 179 
alone once a large number of representative causal variants have been discovered. 180 
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279 Figure 1: eQTL discovery with different genotyping technologies. Number of autosomal 80
eQTLs discovered in each tissue when genotype information is provided by arrays imputed 281 
into a reference panel (genotype) and by whole genome sequencing (sequence). There is a 282 
modest (3.7%) increase in the total number of eQTLs discovered with WGS over all tissues. 283 
Figure 2: Relative enrichment of eQTLs discovered with different genotyping technologies in 284 
functional regions. Odds ratio and P value for enrichment (Fisher's Exact Test) of lead eQTL 285 
variants (LEVs) called from sequence being located in DNase hypersensitivity sites11 relative to 286 
LEVs called from array derived genotypes. A total of 31 experiments related to the tissue from 287 
which RNA-seq was collected were analysed. The code given relates to the Roadmap 288 
Epigenomics code, Supplementary Table 2 lists the original experiment. All but enrichment of 289 
skin eQTLs in DHS assayed in NHDF-Ad Adult Dermal Fibroblast Primary Cells were Bonferroni 290 
significant (two tailed Fisher test, P < 0.05). 291 
Figure 3: Distribution of the CaVEMaN estimated causal probabilities for lead eQTL variants 292 
(LEVs). We show the distribution of causal probabilities for all LEVs discovered in each of the 293 
tissues. 294 
Figure 4: Probability of a lead eQTL variant (LEV) falling into a DHS region against causal 295 
probability. LEVs were divided into ten equally sized groups by causal probability and the 296 
proportion falling into DHS regions calculated for each group and each experiment. The 297 
complete line represents the median result across experiments; where there is more than one 298 
experiment for a given tissue, the dotted lines give the maximum and minimum across 299 
experiments. We observe a linear relationship between the two probabilities. A full list of 300 
experiments can be found in Supplementary Table 2. 301 
Figure 5: Proportion of functional variants falling into regions identified by single ChIP-seq 302 
experiments. We estimated the proportion of LEVs with causal probability of 1 falling into 303 
functional regions defined by the Roadmap Epigenomics Consortium by extrapolating from the 304 
relationship observed in Figure 4. Blood shows the highest proportions falling in annotations, 305 
for all other tissues we estimate only a minority of causal variants are in DHS regions. 306 
Figure 6: High confidence causal variants (HCCVs) statistically associated with GWAS traits. 307 
Numbers of Bonferroni significant associations between HCCVs (causal probability > 0.8) and 308 
GWAS traits, divided by tissue type. HCCVs show more statistical associations with GWAS 309 
traits than other eQTLs, as a co-segregating signal will not be weakened by imperfectly 310 
captured markers. 311 
Online Methods 312 
TwinsUK data 313 
Expression and genotype data from arrays. 314 
RPKM expression quantifications and array genotype data used in this paper have been 315 
previously analysed5,6 and the production of these data is described in full in Supplementary 316 
note 1. 317 
Genotypes called from sequencing. 318 
The vcf files, produced by the UK10K consortium7, were downloaded from the European 319 
Genome-phenome Archive. When one monozygotic twin in the sample had been sequenced, 320 
the same data was used for the genetically identical sibling. Of 856 individuals with 321 
expression, 552 have available sequence data (246 individuals had expression quantified in 322 
whole blood, 505 in adipose tissue, 523 in LCLs and 471 in skin). For multiallelic variants, 323 
dosage was calculated as 2 times the number of copies of the most common allele. Variants 324 
were filtered if the major allele had a frequency >0.99. 325 
Ethics statement. 326 
The St. Thomas’ Research Ethics Committee (REC) approved on 20 September 2007 the 327 
protocol for dissemination of data, including DNA, with REC reference number RE04/015. On 328 
12 March 2008, the REC confirmed this approval extended to expression data. Volunteers 329 
gave informed consent and signed an approved consent form before the biopsy procedure. 330 
Volunteers were supplied with an appropriate detailed information sheet regarding the 331 
research project and biopsy procedure by post before attending for the biopsy. Consent to link 332 
the RNA-seq data with the whole genome sequence data was approved by the TwinsUK 333 
Resource Executive Committee (TREC) on 22nd April 2015. 334 
Geuvadis data. 335 
BAM files for RNA-seq were downloaded from EBI ArrayExpress, accession code E-GEUV-3. 336 
These were mapped to the GRCh37 reference genome33 using GEM version 1.7.134 and protein 337 
coding and lincRNAs were quantified using the GENCODE v19 annotation35. Population group 338 
was regressed out of RPKM values using a linear model, values were centred and scaled to 339 
mean 0, variance 1, and 50 principal components were removed. Genotype vcf files from 340 
phase 3 of the 1000 Genomes project36 were downloaded from the 1000 Genomes website. In 341 
non-pseudo autosomal regions of the X chromosome, male dosage was calculated as twice the 342 
number of copies of the alternate allele. A minor allele frequency cut off of 0.01 was applied. 343 
eQTL mapping. 344 
eQTLs were mapped using fastQTL which tests for association between expression and 345 
genotype with a two-tailed Wald test37. To discover multiple independent eQTLs, a stepwise 346 
regression procedure was applied. Firstly, for each tissue, fastQTL was run with 10,000 347 
permutations to discover a set of eGenes (FDR <0.01). Then, the maximum beta-adjusted P 348 
value (correcting for multiple testing across SNPs) over these genes was taken as the gene-349 
level threshold. The next stage proceeded iteratively for each gene. At each iteration a cis scan 350 
of the window was performed, using 10,000 permutations and correcting for all previously 351 
discovered SNPs. If the beta adjusted P value for the LEV was not significant at the gene-level 352 
threshold, the procedure moved on to the backward step. If this P value was significant, the 353 
LEV was added to the list of discovered eQTLs as an independent signal and the forward step 354 
proceeded to the next iteration. 355 
Once the forward stage was complete for a given gene, a list of associated SNPs was produced 356 
which we refer to as forward signals. The backwards stage consisted of testing each forward 357 
signal separately, controlling for all other discovered signals. For each forward signal we ran a 358 
cis scan over all variants in the window using fastQTL, fitting all other discovered signals as 359 
covariates. If no SNP is significant at the gene-level threshold the signal being tested is 360 
dropped, otherwise the LEV from the scan was chosen as the variant that represented the 361 
signal best in the full model. 362 
Properties of LEVs estimated using sequence and genotyping arrays. 363 
We investigated the differences between LEVs identified using sequence data and data from 364 
genotyping arrays to better understand the slight increase in power we see using sequence. 365 
The minor allele frequency (MAF) of eQTLs called using sequence is slightly lower than those 366 
identified using genotype data (median MAF of 26.0% compared to 27.4%, two tailed Mann-367 
Whitney U test P=5.52×10-21, Supplementary Figure 2). We find that 3,383 out of 22,656 LEVs 368 
called using sequence are removed from the array data due to INFO score less than 0.8, the 369 
majority of these failed imputation criteria based on the HumanHap300 array (3,334 failed on 370 
this array, 2,290 failed on the HumanHap610Q, and 2,241 failed on both, Supplementary 371 
Figure 3). Finally, for remaining 19,273 sequence LEVs where the genotype imputation passed 372 
the quality filters, we see good agreement between calls made using the two technologies, 373 
with a median proportion of different calls of only 0.94%. However, there are a small minority 374 
of LEVs (0.93%) where we see a larger discrepancy between the two call sets, with more than 375 
10% of individuals showing differences. Together, these results suggest that both genotyping 376 
arrays with more SNPs and larger reference panels which enumerate more haplotypes will 377 
further reduce the power differences between studies using sequencing and those using 378 
genotyping arrays. 379 
Enrichment analysis. 380 
Bed files listing DNase hypersensitivity sites, produced by the Roadmap Epigenomics 381 
consortium38, were downloaded from the NCBI ftp site. Experiments were linked to tissues for 382 
which RNA-seq was available using Supplementary Table 2. Over each ChIP-seq RNA-seq 383 
combination, the odds ratio for enrichment was calculated using the number of LEVs called 384 
using sequence and the number of LEVs called using array-based genotypes falling within 385 
regions called in the experiment and the total numbers of eQTLs. A two tailed Fisher’s Exact 386 
test was performed to test the hypothesis that equal proportions of sequence and genotype 387 
LEVs fell in these regions. 388 
Simulations. 389 
For all discovered eQTLs, the LEV for association was identified and its minor allele frequency 390 
and distance to the transcription start site calculated. Beta and sigma coefficients from a 391 
regression of expression on the LEV were also estimated. Then a matched SNP was chosen, 392 
with a distance to transcription start site of a gene within 1 kb of the original, and minor allele 393 
frequency within 0.025. Simulated expression was produced by multiplying SNP genotype by 394 
beta and adding a random normally distributed term with standard error of sigma. Five 395 
simulated datasets were produced for each TwinsUK tissue, eQTL mapping was applied to 396 
each looking only for primary eQTLs, and the rank of the nominal P value for the causal variant 397 
was collected. 398 
CaVEMaN. 399 
A frequentist definition of a causal probability. 400 
A number of methods have been proposed using Bayesian methodologies to estimate the 401 
probability that a variant is causal for an effect on expression, combining prior distributions 402 
with likelihoods to estimate posterior probabilities15,39,40. We, however, use a frequentist 403 
definition of the probability of being causal. Causal probabilities are assigned to LEVs with the 404 
following property: if an eQTL is sampled randomly from the set of all eQTLs that have a causal 405 
probability equal to a number x, the probability that a causal variant is chosen is equal to x. In 406 
this way it matches an intuitive understanding of what a causal probability is: if a LEV is chosen 407 
at random, the probability that a causal variant will be chosen is equal to the estimate from 408 
CaVEMaN. 409 
Learning parameter estimates from simulations. 410 
Firstly, we used the simulations where a specific variant has been chosen to act as the causal 411 
variant to estimate the probability the causal variant would be the ith ranked SNP in an eQTL 412 
mapping. This is done by calculating the proportion of times this occurred across all tissues 413 
and simulations (this quantity is denoted pi, Supplementary Figure 1). As CaVEMaN focuses on 414 
the top 10 ranked variants from an eQTL analysis, pi, i from 1 to 10, were normalised to sum 415 
up to 1. 416 
Multiple variants affecting expression of one gene. 417 
Previous fine-mapping approaches can be categorised into two classes: those that assume 418 
only one genetic signal affects the phenotype39, and those which map multiple genetic signals 419 
simultaneously15,40. CaVEMaN takes a different approach, in that the procedure is separated 420 
into two steps: firstly, a stepwise regression approach is used to estimate the number of eQTL 421 
affecting the expression of the gene, and then each independent eQTL is mapped separately. 422 
The advantage of this is there exists a well-grounded statistical methodology for answering 423 
the question of multiple independent variables affecting expression which deals with issues of 424 
multiple testing and significance. 425 
Once a set of eGenes and the independent eQTLs affecting them has been identified, we 426 
create new “single signal” expression phenotypes. For each eQTL these are made by 427 
regressing out all other eQTLs discovered for the gene, producing an expression phenotype 428 
which reflects the signal from only one eQTL. 429 
Calculating CaVEMaN score. 430 
This new matrix of expression data was sampled with replacement 10,000 times to create 431 
10,000 new datasets of the same size. A cis eQTL mapping testing association using a two 432 
tailed test for significant correlation was run on each of these datasets, and the proportion of 433 
times a given SNP was ranked i, i from 1 to 10 was calculated (denoted by Fi, this is an 434 
estimate of the probability that SNP would be the rank ith most associated SNP). The CaVEMaN 435 
score was defined as ∑ 𝑝𝑖𝐹𝑖
10
𝑖=1 , i.e., the sum of the product of the probability the SNP is 436 
ranked i in an eQTL analysis with the probability the ith ranked SNP is causal for the 437 
association. 438 
Calibrating CaVEMaN score for LEVs using simulations. 439 
Finally, we further exploited the simulations to calibrate the CaVEMaN score of the LEV. 440 
CaVEMaN was run on all simulated data. Then, across all simulated datasets (removing blood 441 
as this was an outlier resulting in less conservative estimates of causal probabilities) we 442 
divided the CaVEMaN scores of the LEVs into twenty quantiles. Within each quantile, we 443 
calculated the proportion of times the lead SNP was the causal SNP and then drew a 444 
monotonically increasing smooth spline from the origin, through the 20 quantiles, to the point 445 
(1, 1) using the gsl interpolate functions with the steffen method (gsl-2.1, Supplementary 446 
Figure 4). This function provides our mapping of CaVEMaN score of the lead SNP onto causal 447 
probabilities, and we applied this function to the CaVEMaN scores of the LEV to estimate their 448 
causal probabilities. 449 
Validating the method with simulations in the Geuvadis data. 450 
The CaVEMaN method uses parameters estimated from simulations based on the UK10K 451 
expression data (chiefly the distribution of ranks of causal eQTLs and the relationship between 452 
CaVEMaN score and causal probability), meaning that these simulations cannot later be used 453 
to validate the CaVEMaN estimates. We have run further simulations using the Geuvadis data 454 
to demonstrate that the estimates of the causal probability for the LEVs are well calibrated, 455 
when parameters are estimated from separately from the dataset being analysed. A total of 456 
five simulations were run, again using effect size and residual variance estimated from the 457 
original data. In Supplementary Figure 5 we plot binned estimates of the estimated causal 458 
probabilities against the proportion of times the LEV is the causal variant. We see good 459 
agreement between our estimates and the true causal probabilities for these bins: the 460 
minimum, median and maximum difference between the estimate and the true values are 461 
0.0056, 0.036 and 0.071 respectively. 462 
In addition to this, we have run a further simulation to test the behaviour of the model when 463 
there are weaker eQTL effects which are not detected by the original multiple eQTL mapping 464 
strategy. As before, we simulate a primary eQTL with minor allele frequency, effect size and 465 
distance to the transcription start site matched to an eQTL discovered in the original analysis. 466 
Then, a second variant is chosen randomly in the cis window, with minor allele frequency 467 
greater than 0.05, and we use this variant to simulate an extra eQTL effect on the phenotype, 468 
with effect size one half of the primary eQTL. Then a residual noise term was generated such 469 
that the primary eQTL explains the same proportion of variance as the original matched eQTL. 470 
In Supplementary Figure 5 we see that there is still good agreement when estimating the 471 
causal probabilities of the primary eQTL to the known ground truth. 472 
Comparing results on TwinsUK LCL data with results from CAVIAR. 473 
CAVIAR, along with equivalent Bayesian methods16-19, have previously been suggested as fine-474 
mapping methods for estimating credible sets of SNPs with a given probability of containing 475 
the causal variant. For genes with an eQTL in LCLs, we applied CAVIAR14 to produce another 476 
estimate of causal variant probability for comparison. As CAVIAR is limited in the number of 477 
SNPs it can analyse, we first extracted all variants with P < 0.01, up to the first 50. The Z scores 478 
for these variants were produced, with the correlation matrix of these SNPs, and CAVIAR was 479 
run with the default settings. There was good agreement on the causal probabilities of the LEV 480 
(spearman ρ = 0.856, P < 10-216, Supplementary Figure 6), but the CAVIAR method produced 481 
more conservative estimates of the causal probabilities (median probability 0.12 vs 0.29). As 482 
the CaVEMaN estimates are calibrated using simulations, this suggests that the CAVIAR 483 
estimates are on average underestimates of the true probabilities, which could be due to a 484 
combination the priors not reflecting the true regulatory landscape and the sample size being 485 
insufficient to overcome this. CAVIAR does not suggest adjusting the priors when studying 486 
expression rather than GWAS trait associations, despite the fundamentally different genetic 487 
architectures and sample sizes between these types of studies. The approach of calibrating 488 
estimates of probabilities using simulations could also be easily extended to other fine 489 
mapping methods such as CAVIAR. 490 
Comparison of simulation results with those produced using dap-g. 491 
We have compared the results of CaVEMaN when applied to one of the simulation datasets to 492 
results produced using dap-g15, a recent method proposed for fine-mapping. For each 493 
simulated gene expression, all SNPs in the cis window were extracted and dap-g was run, 494 
specifying the option -ld_control 0.25. Then, for a comparable estimate of the posterior 495 
probability of the LEV, we extracted the highest posterior probability of any single variant 496 
model, and conditioned this on only one genetic signal by dividing this by the sum of the 497 
posterior probabilities of all single SNP models. The two methods identify exactly the same 498 
sets of LEVs and there is good agreement between the estimates of causal probabilities 499 
(Spearman ρ = 0.95, P<10-216). However, plotting the causal probabilities against the 500 
proportion of LEVs which are the causal variants, we see that dap-g underestimates this 501 
quantity (Supplementary Figure 5).                                                                                                                                                                502 
Application of simulations to other datasets. 503 
The Geuvadis dataset differs in many aspects from the TwinsUK data that the CaVEMaN 504 
method was trained on: Geuvadis samples were sequenced in multiple laboratories rather 505 
than just one, Geuvadis uses a multi-ethnic cohort implying a different linkage structure in the 506 
genome, a different mapper (in particular, a splice-aware mapper) was used to quantify the 507 
data, and the tissue type, sample size and ability to map eQTLs are all different from three out 508 
of four TwinsUK tissues. This shows the parameters estimated in TwinsUK are robust to a 509 
range of factors. However, in the future, similar datasets with thousands of samples are 510 
expected and it is possible that our proposed method will not generalise to this case. For this 511 
reason, we provide methods to repeat these simulations in new datasets, described on the 512 
accompanying website. 513 
Statistical associations between eQTLs and GWAS traits from summary statistics. 514 
We have downloaded the GWAS summary statistics for 16 different GWAS traits: autism41, 515 
birth weight42, body mass index (analysing all ancestries)43, coronary artery disease44, Crohn’s 516 
disease45, diabetes46, fasting glucose47, fasting insulin47, height48, high-density lipoprotein49, 517 
irritable bowel disease45,50, low-density lipoprotein49, schizophrenia50,51, total cholesterol49, 518 
triglycerides49, and ulcerative colitis45. Data on birth weight trait has been contributed by the 519 
EGG Consortium using the UK Biobank Resource and has been downloaded from www.egg-520 
consortium.org. For all LEVs, the P value for each trait was extracted (if available) and the 521 
qvalue package21 was used to estimate π1, the proportion of alternate hypotheses (i.e., 522 
association between variant and GWAS trait). Finally, Bonferroni significant GWAS associations 523 
for HCCVs were reported, controlling for multiple testing across all phenotypes and variants. 524 
Testing HCCVs associated with GWAS traits for co-segregation using coloc. 525 
For HCCVs significantly associated with GWAS traits, we used the coloc method24 to test the 526 
hypothesis of shared causal mechanism. P values for association, available for both expression 527 
and GWAS associations, were extracted in a 200,000bp region around the eQTL. Minor allele 528 
frequencies for the variants were extracted from the 1000 Genomes Phase 3 release36. After 529 
running coloc, we report the probability of a shared causal variant for both associations, 530 
conditional on genuine associations existing for both traits (P(H3) / (P(H3) + P(H4)) reported by 531 
coloc). 532 
Regulatory Trait Concordance method for testing for co-segregation with the NHGRI-EBI 533 
catalog GWAS associations. 534 
We downloaded the NHGRI-EBI Catalog of reported genome-wide significant associations 535 
from the EBI website on the  September 2016 and removed all with P>5×10-8 and where the 536 
variant was not listed in dbSNP build 14852, leaving 11,636 reported associations. RTC, as 537 
implemented in QTLtools 53, was applied with the default settings to look for sharing of these 538 
GWAS variants with eQTLs. As the RTC statistic is uniformly distributed under the null 539 
hypothesis of two separate causal loci independently located within the hotspot, 1 - RTC can 540 
be interpreted as a P value for a shared causal variant. The qvalue package21 estimated π1, the 541 
proportion of GWAS/eQTLs signals in the same recombination interval with the same causal 542 
variant. 543 
Code availability. 544 
Code for correcting the expression datasets for multiple eQTLs, running the CaVEMaN 545 
method, converting the CaVEMaN score to a causal probability and repeating simulations on 546 
new datasets can be found here: 547 
https://github.com/funpopgen/CaVEMaN. 548 
Data availability 549 
BAM files for the RNA-seq are available from EBI ArrayExpress, accession code E-GEUV-3 550 
(Geuvadis cohort) and the European Genome-Phenome Archive, study ID EGAS00001000805 551 
(TwinsUK cohort). Whole genome sequence is available from the European Genome-Phenome 552 
Archive, study ID EGAS00001000108 (TwinsUK) and the 1000 Genomes website (Geuvadis). 553 
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